Results from a multinational Phase 2 clinical study (Protact Trial) of siRNA directed against the oncogenic KRAS G12D and G12V mutations  in an extended release formulation (Loder™) was presented at the 2023 European Society for Medical Oncology (ESMO) annual congress (Abstract 1626P). The key endpoint was an overall survival advantage in non-resectable localized pancreatic cancer patients that bear the KRAS G12D/V mutation when treated with the Loder™plus standard of care chemotherapy vs standard of care chemotherapy.  

About 90% of pancreatic cancer patients have a mutagenic  KRAS mutation and  Silexion’s product is directed to about 75% of the KRAS mutations for this cancer population.  The life expectancy of these patients treated with standard of care chemotherapy is about 14 months.

About ESMO

ESMO is the European Society for Medical Oncology. Representing more than 34,000 oncology professionals in 170 countries, ESMO is a reference for oncology education and information.

Founded in 1975, ESMO has European roots with a global reach. Home for all oncology stakeholders, ESMO connects professionals with diverse expertise and experience. Its education and information resources support an integrated multi-professional approach to cancer care, from a medical oncology perspective.

ESMO seeks to erase boundaries in cancer care, whether between countries or specialities, and pursue its mission across oncology, worldwide.